Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease HPO
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Aromatase inhibitors target the production of estrogen in breast adipose tissue, but in doing so, also decrease estrogen formation in bone and other sites, giving rise to deleterious side effects, such as bone loss and arthralgia. 16357189 2005
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Aromatase inhibitors (AIs) play an important role in the adjuvant treatment of hormone receptor-positive breast cancer, but they are associated with bone loss and increased fracture risk. 30474104 2018
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE About half of the 391 patients treated with AIs in the Barcelona-Aromatase induced bone loss in early breast cancer cohort suffered a significant bone loss at lumbar spine (LS) and/or femoral neck (FN) after 2 years on AI-treatment. 26108486 2015
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Adjuvant aromatase inhibitor (AI) therapy, for hormone receptor-positive breast cancer, in postmenopausal women is associated with bone loss, leading to an increased risk of fractures. 29520506 2019
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Adjuvant use of gonadotropin-releasing hormone analogues, which can also be used in metastatic disease, in combination with tamoxifen in premenopausal women, and aromatase inhibitors in postmenopausal women with hormone-sensitive breast cancer, causes rapid bone loss and fragility fractures. 29572126 2018
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Age, breast cancer history, prior chemotherapy, and tamoxifen or aromatase inhibitor (AI) use were not associated with having osteoporosis or osteopenia. 26086567 2015
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Although adjuvant aromatase inhibitor (AI) therapy is widely used in postmenopausal women with hormone receptor-positive breast cancer, it is known to be associated with bone loss and increased fracture risk. 29116414 2018
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 AlteredExpression disease BEFREE Although, third-generation aromatase inhibitors (AIs) are used as first-line treatment in post-menopausal women, they cause endocrine resistance and bone loss, which limits their success. 28396197 2017
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Both bisphosphonates and denosumab prevent bone loss; additionally, denosumab has proven anti-fracture benefit in post-menopausal women receiving aromatase inhibitors for hormone receptor-positive breast cancer. 31318068 2019
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. 30223134 2018
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE By reducing estrogen levels aromatase inhibitors (AI) as part of breast cancer therapy promote bone loss. 31694630 2019
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study. 30022834 2018
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE Estrogen and the estrogen receptor (ER) play a central role in bone metabolism as illustrated by the loss of bone mass after menopause and the osteopenia in individuals with defect aromatase or ER. 11092403 2000
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE However, aromatase inhibitors cause major side effects such as bone loss and abnormal lipid metabolism, due to indiscriminate reduction of aromatase activity in all expression sites of the body. 18614276 2009
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE However, a significant association was observed between the CYP19 genotype and BMD change at the distal forearm; the highest bone loss was observed in subjects homozygotic for the shortest observed allele length of (TTTA)(7)-repeats (P < 0.02). 12843146 2003
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE In contrast to the protective effect of tamoxifen, aromatase inhibitors are linked with an increased risk for bone loss and fractures. 28403774 2017
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE In fact, therapy with aromatase inhibitors is associated with bone loss and fractures. 15794932 2005
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE Inactivating mutations of the aromatase gene are associated with decreased bone mineral density in both men and women. 11344237 2001
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE It is well known that anti-estrogen therapy (AET), especially aromatase inhibitors (AI), is associated with rapid bone loss and thus increases the risk of osteoporosis. 29981903 2018
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 AlteredExpression disease BEFREE Moreover, with aging, individual differences in aromatase activity and thus in estrogen levels may significantly affect bone loss and fracture risk in both genders. 21874760 2011
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Osteoporosis (OP) risk factor assessment and bone mineral density (BMD) testing are frequently omitted at baseline in aromatase inhibitor (AI) studies, which may lead to misinterpretation of AI associated bone loss. 30939140 2019
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 Biomarker disease BEFREE Our findings suggest the usefulness of addition of risedronate in order to prevent aromatase inhibitors-related bone loss, not only in case of high-risk of fractures, but also for women at mild-moderate risk. 28955236 2017
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE Perimenopausal bone mass or bone loss in untreated women was not associated with the CYP19 polymorphisms. 14517714 2004
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.200 GeneticVariation disease BEFREE Polymorphisms in the CYP19A1 (aromatase) gene influence disease-free survival and bone loss in patients taking aromatase inhibitors (AIs) for estrogen receptor-positive (ER+) breast cancers. 26049585 2015